4th International Symposium on New Quinolones: proceedings of a the 4th International Symposium on New Quinolones held at Munich, Germany, August 27 - 29, 1992
Gespeichert in:
| Körperschaft: | |
|---|---|
| Format: | Tagungsbericht Buch |
| Sprache: | English |
| Veröffentlicht: |
Auckland [u.a.]
Adis Internat.
1993
|
| Schriftenreihe: | Drugs
Supplement ; 45,3 |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | Literaturangaben |
| Beschreibung: | XX, 475 S. Ill., graph. Darst. |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV008163353 | ||
| 003 | DE-604 | ||
| 005 | 20040227 | ||
| 007 | t | ||
| 008 | 930809s1993 ad|| |||| 10||| eng d | ||
| 035 | |a (OCoLC)231552544 | ||
| 035 | |a (DE-599)BVBBV008163353 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-19 |a DE-12 |a DE-355 | ||
| 111 | 2 | |a International Symposium on New Quinolones |n 4 |d 1992 |c München |j Verfasser |0 (DE-588)1300985-0 |4 aut | |
| 245 | 1 | 0 | |a 4th International Symposium on New Quinolones |b proceedings of a the 4th International Symposium on New Quinolones held at Munich, Germany, August 27 - 29, 1992 |c organising committee E. Rubinstein (chairman) ... |
| 246 | 1 | 3 | |a Fourth International Symposium on New Quinolones |
| 264 | 1 | |a Auckland [u.a.] |b Adis Internat. |c 1993 | |
| 300 | |a XX, 475 S. |b Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Drugs : Supplement |v 45,3 | |
| 500 | |a Literaturangaben | ||
| 650 | 0 | 7 | |a Gyrasehemmer |0 (DE-588)4217839-3 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)1071861417 |a Konferenzschrift |y 1992 |z München |2 gnd-content | |
| 689 | 0 | 0 | |a Gyrasehemmer |0 (DE-588)4217839-3 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Rubinstein, Ethan |e Sonstige |4 oth | |
| 830 | 0 | |a Drugs |v Supplement ; 45,3 |w (DE-604)BV000904909 |9 45,3 | |
| 856 | 4 | 2 | |m GBV Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=005385939&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-005385939 | ||
Datensatz im Suchindex
| _version_ | 1804122545547378688 |
|---|---|
| adam_text | ADO DRUGS ^RT~3SUPPLEMENT ^J C * R- 4TH INTERNATIONAL SYMPOSIUM ON NEW
QUINOLONES PROCEEDINGS OF THE 4TH INTERNATIONAL SYMPOSIUM ON NEW
QUINOLONES HELD AT MUNICH, GERMANY, AUGUST 27-29, 1992 ORGANISING
COMMITTEE E. RUBINSTEIN (CHAIRMAN) D. ADAM C. CARBON R. MOELLERING F.
WALDVOGEL TECHNICAL EDITOR HARRIET M. BRYSON THIS SUPPLEMENT IS A
COOPERATIVE PUBLISHING VENTURE OF ADIS INTERNATIONAL LIMITED AND THE 4TH
ISNQ ORGANIZING COMMITTEE COPYRIGHT: 1993 ADIS INTERNATIONAL LIMITED.
ALL RIGHTS RESERVED. NO PART OF THIS PUBLICATION MAY BE REPRODUCED OR
TRANSMITTED IN ANY FORM OR BY ANY MEANS ELECTRONIC OR MECHANICAL
INCLUDING PHOTOCOPYING OR RECORDING OR BY ANY INFORMATION STORAGE AND
RETRIEVAL SYSTEM WITHOUT PERMISSION IN WRITING FROM THE PUBLISHER.
ALTHOUGH GREAT CARE HAS BEEN TAKEN IN COMPILING AND CHECKING THE
INFORMATION GIVEN IN THIS PUBLICATION TO ENSURE THAT IT IS ACCURATE THE
AUTHORS THE PUBLISHER AND THEIR SERVANTS OR AGENTS SHALL NOT BE
RESPONSIBLE OR IN ANY WAY LIABLE FOR THE CONTINUED CURRENCY OF THE
INFORMATION OR FOR ANY ERRORS OMISSIONS OR INACCURACIES IN THIS
PUBLICATION WHETHER ARISING FROM NEGLIGENCE OR OTHERWISE HOWSOEVER OR
FOR ANY CONSEQUENCES ARISING THEREFROM. THE APPEARANCE OF THE CODE AT
THE HEAD OF THE FIRST PAGE OF AN ARTICLE IN THIS JOURNAL INDICATES THE
COPYRIGHT OWNER S CONSENT THAT COPIES OF THE ARTICLE MAY BE MADE FOR THE
PERSONAL OR INTERNAL USE OF SPECIFIC CLIENTS. THIS CONSENT IS GIVEN ON
THE CONDITION, HOWEVER, THAT THE COPIER PAY THE STATED PER COPY FEE
THROUGH THE COPYRIGHT CLEARANCE CENTER INC., 21 CONGRESS STREET, SALEM,
MASSACHUSETTS 01970, USA, FOR COPYING BEYOND THAT PERMITTED BY SECTIONS
107 OR 108 OF THE US COPYRIGHT LAW. THIS CONSENT DOES NOT EXTEND TO
OTHER KINDS OF COPYING SUCH AS COPYING FOR GENERAL DISTRIBUTION, FOR
ADVERTISING OR PROMOTIONAL PURPOSES, FOR CREATING NEW COLLECTIVE WORKS,
OR FOR RESALE. DRAGS IS INDEXED IN CURRENT CONTENTS, INDEX MEDICUS AND
EXCERPTA MEDICA. PUBLISHER S NOTE: THE OPINIONS EXPRESSED IN THIS
PUBLICATION ARE THOSE OF THE INDIVIDUAL AUTHORS, AND ARE NOT
ATTRIBUTABLE TO THE PUBLISHER, EDITOR OR EDITORIAL BOARD OF DRUGS. VOL.
45, SUPPLEMENT 3, 1993 DRUGS - . ,, I SUPPLEMENT ^ J CM XIX-XX ; LIST
OF CONTRIBUTORS XXI FOREWORD E. RUBINSTEIN STATE-OF-THE-ART
PRESENTATIONS 1-7 THE FUTURE OF THE QUINOLONES ANDRIOLE VT 8-14
QUINOLONE MODE OF ACTION - NEW ASPECTS HOOPER DC 15-23 MECHANISMS OF
RESISTANCE TO QUINOLONES CAMBAU E, GUTMANN L 24-28 THE EPIDEMIOLOGY OF
BACTERIAL RESISTANCE TO QUINOLONES ACAR JF, O BRIEN TF, GOLDSTEIN FW,
JONES RN 29-36 QUINOLONES IN INTRACELLULAR INFECTIONS PECHERE J-C 37-41
USE OF THE QUINOLONES IN PAEDIATRICS SCHAAD UB 42-45 THE USE OF
QUINOLONES IN DEVELOPING COUNTRIES RODRIGUEZ-NORIEGA E, MORFIN-OTERO R,
ESPANA-AHUMADA S 46-53 POSTMARKETING SURVEILLANCE OF QUINOLONES, 1990 TO
1992 DAVEY P, MCDONALD T 54-58 SYNERGY AND ANTAGONISM OF
FLUOROQUINOLONES WITH OTHER CLASSES OF ANTIMICROBIAL AGENTS NEU HC 59-64
SAFETY AND TOLERABILITY OF FLUOROQUINOLONES NORRBY SR, LIETMAN PS 65-72
FLUOROQUINOLONES: INTERACTION PROFILE DURING ENTERAL ABSORPTION
DEPPERMANN K-M, LODE H 73-80 USE OF THE QUINOLONES FOR THE PROPHYLAXIS
AND THERAPY OF INFECTIONS IN IMMUNOCOMPROMISED HOSTS MASCHMEYER G 81-90
USE OF THE QUINOLONES IN THE PROPHYLAXIS AND TREATMENT OF
GRANULOCYTOPENIC IMMUNOCOMPROMISED CANCER PATIENTS VAN DER AUWERA P,
GERAIN J 91-97 QUINOLONES IN THE TREATMENT OF LOWER RESPIRATORY TRACT
INFECTIONS IN ADULT PATIENTS CARBON C CONTENTS 98-101 FLUOROQUINOLONES
IN THE TREATMENT OF CYSTIC FIBROSIS HEIIBY N, PEDERSEN SS, JENSEN T,
VALERIUS NH, KOCH C 102-113 FLUOROQUINOLONES AND SURGICAL PROPHYLAXIS
DELLAMONICA P, BERNARD E 114-118 QUINOLONES IN THE TREATMENT OF ACUTE
BACTERIAL DIARRHOEAL DISEASES AKALIN HE 119-124 QUINOLONES IN SALMONELLA
TYPHI INFECTION DUPONT HL 125-133 IMPACT OF THE FLUOROQUINOLONES ON
GASTROINTESTINAL FLORA KORTEN V, MURRAY BE 134-138 QUINOLONES IN
SEXUALLY TRANSMITTED DISEASES RIDGWAY GL 139-144 MANAGEMENT OF LOWER
URINARY TRACT INFECTIONS BAILEY RR POSTER PRESENTATIONS MECHANISM OF
ACTION 145-147 HYDROPHOBICIT Y OF 11 FLUOROQUINOLONES AND ANTIBACTERIAL
ACTIVITY, I ACTIVITY AGAINST DNA GYRASE AND UPTAKE BAZILE S, MOREAU NJ,
BOUZARD D, ESSIZ M X 148-149 AFFINITY OF SPARFLOXACIN AND 4 OTHER
FLUOROQUINOLONES FOR MAGNESIUM AND EFFECT ON ANTIBACTERIAL ACTIVITY
LECOMTE S, COUPRY C, CHENON MT, MOREAU NJ 150-151 : EFFECT OF CATIONS
AND EDTA UPON THE ACTIVITY OF 18 QUINOLONES, I GENTAMICIN, CEFTAZIDIME
AND POLYMIXIN AGAINST GRAM-NEGATIVE AND ; GRAM-POSITIVE BACTERIA :
MARSHALL AJH, PIDDOCK UV EPIDEMIOLOGICAL SURVEILLANCE AND QUINOLONES
RESISTANCE 152-156 , SENSITIVITY OF COMMUNITY- AND HOSPITAL-ACQUIRED
BACTERIAL ISOLATES TO | SPARFLOXACIN IN COMPARISON WITH OTHER
ANTIBIOTICS ! FOCHT J, NBSNER K, KRESKEN M 157-158 [ ANTIMICROBIAL
ACTIVITIES OF CIPROFLOXACIN AND 6 OTHER NEW QUINOLONES IN VITRO AGAINST
RECENT CLINICAL PATHOGENS NAKASHIO S, HORI S, SHIMADA J 159-160 ,
COMPARATIVE IN VITRO ACTIVITY OF OFLOXACIN AND OTHER ANTIMICROBIAL
AGENTS USED IN ORAL THERAPY IN GENERAL PRACTICE FOCHT J, KRAUS H, NBSNER
K CONTENTS 161-162 J 6 YEARS OF EXPERIENCE WITH SENSITIVITY TESTING OF
VARIOUS GRAM-NEGATIVE AND GRAM-POSITIVE CLINICAL STRAINS TO OFLOXACIN
ZAREMBA M, ROZKIEWICZ M, PYDZINSKA J, DOMAHSKA T, BOROWSKI J 163-164 MIC
AUDIT OF ROUTINE CIPROFLOXACIN SENSITIVITY TESTING KING A, PHILLIPS I,
AMYES S, PATON R, LEWIN C, TILLOTSON G 165-166 ANNUAL CHANGES IN THE
SUSCEPTIBILITY OF CLINICAL ISOLATES TO OFLOXACIN TAKUBO T 167-169 THE
NORTH AMERICAN COMPONENT (USA, CANADA) OF AN INTERNATIONAL COMPARATIVE
MIC TRIAL MONITORING OFLOXACIN RESISTANCE HOBAN D, JONES RN 170-171
SURVEILLANCE OF BACTERIAL RESISTANCE TO QUINOLONES WANG FU, ZHU DE-MEI,
WANG YU-QING 172-173 CLINICAL AND EXPERIMENTAL STUDY OF THE APPEARANCE
OF NORFLOXACIN-RESISTANT P. AERUGINOSA IN UTI ONODERA S, KIYOTA H, GOTO
H, MACHIDA T, IYOBE S 174-175 PREVALENCE OF CIPROFLOXACIN RESISTANCE IN
MULTIRESISTANT GRAM-NEGATIVE INTENSIVE CARE UNIT ISOLATES KHURANA CM,
WOJACK BR 176 HIGH LEVEL QUINOLONE RESISTANCE AMONG ESCHERICHIA COLI
CLINICAL ISOLATES ALARCBN T, PITA J, PIDDOCK LJV, LBPEZ-BREA M 177-178
EMERGENCE OF RESISTANCE OF UROPATHOGENS TO QUINOLONES NABER KG, WITTE W,
BAUERNFEIND A, WIEDEMANN B 179 RESISTANCE TO QUINOLONES AND OTHER
ANTIBIOTICS ASSESSED BY FACTOR ANALYSIS LEIBOVICI L, WYSENBEEK AJ,
KONISBERGER H, SAMRA Z, PITLIK SD, DRUCKER M NEW QUINOLONES 180 IN VITRO
AND IN VIVO ANTIBACTERIAL ACTIVITY OF E-4868 XICOTA MA, COLL R, ESTEVE
M, PARES M, GUINEA J 181 IN VITRO ACTIVITIES OF AM-1155 AGAINST
CHLAMYDIA SPP. AND M. AVIUM COMPLEX SOEJIMA R, MIYASHITA N, NAKABAYASHI
M, KIMURA M, HASHIGUCHI K, KISHIMOTO T, NIKI Y 182-183 IN VITRO
ANTIBACTERIAL ACTIVITY OF AM-1155 HIRAI K, YASUE T, HOSAKA M,
WAKABAYASHI E, TOMIZAWA H, NISHINO K 184-186 COMPARATIVE IN VITRO
ACTIVITY OF AM-1155, A NEW QUINOLONE, AGAINST ANAEROBIC BACTERIA UENO K,
WATANABE K, KATO N, KATO H, BANDOH K, TANAKA Y 187 IN VITRO ACTIVITY OF
PD 131628 AGAINST ANAEROBIC BACTERIA NORD CE, HAGELBACK A CONTENTS
188-189 COMPARATIV E IN VITRO ACTIVITY OF PD 131628, THE
MICROBIOLOGICALLY ACTIVE CONSTITUENT OF THE PRODRUG CI-990 (PD 131112) ;
FELMINGHAM D, ROBBINS MJ, GHOSH G, MEHTA M, LEAKEY A, CLARK S, MUMTAZ G,
RIDGWAY GL, ! GRUNEBERG RN 190-191 ; IN VITRO ACTIVITY OF PD 131628 AND
EFFECTS ON VIRULENCE AND OMPS ; CIPRIANI P, GIORDANO A, MAGNI A,
TRANCASSINI M, FILADORO F 192-193 COMPARATIVE IN VITRO ANTIBACTERIAL
ACTIVITY OF PD 131628, THE ACTIVE METABOLITE OF CI-990 CALLANAN JJ,
RODITI DOJ, FORDER AA ACTIVITY OF QUINOLONES AGAINST STREPTOCOCCUS
PNEUMONIAE 194-195 SUSCEPTIBILITY OF 170 PENICILLIN-SUSCEPTIBLE AND
-RESISTANT PNEUMOCOCCI TO VARIOUS ANTIMICROBIALS SPONGIER SK, JACOBS
MR, APPELBAUM PC 196-197 ACTIVITY OF QUINOLONE ANTIBACTERIALS AGAINST
STREPTOCOCCUS PNEUMONIAE MORRISSEY I, SMITH JT 198 INDUCTION OF
RESISTANCE OF STREPTOCOCCUS PNEUMONIAE TO LEVOFLOXACIN, CIPROFLOXACIN
AND NORFLOXACIN IN VITRO ; FU KP, LAFREDO SC, FOLENO BD ACTIVITY OF
QUINOLONES AGAINST STAPHYLOCOCCI 199-200 COMPARATIVE IN VITRO ACTIVITY
OF SPARFLOXACIN AGAINST GRAM-POSITIVE COCCI ; KOCAGBZ S, GIIR D, UZUN O,
OZKUYUMCU C, AKOVA M, AKALIN HE 201 I INCREASED INCIDENCE OF
GRAM-POSITIVE PATHOGENS SUBSEQUENT TO I QUINOLONE THERAPY IN UTI I
TAUFER M, MAILER H, PUMMER K, WANDSCHNEIDER G 202 RESISTANCE MECHANISM
OF MRSA TO QUINOLONES I ZHANG YONG-XIN, ZHU DE-MEI, WANG F, TANAKA M,
SATO K, OSADA Y 203 CLONAL DISSEMINATION OF QR-MRSA RESULTING FROM
INAPPROPRIATE ; HOSPITAL HYGIENE AND PROPHYLAXIS I WITTE W, HEUCK D
204-205 IN VITRO ACTIVITY OF 5 QUINOLONES, COTRIMOXAZOLE, IMIPENEM, AND
RIFAMPICIN AGAINST RECENT ISOLATES OF S. AUREUS HUSAIN N, MANZOR O,
MARKOWITZ N, SARAVOLATZ L 206-207 ADVANTAGES OFFERED BY SPARFLOXACIN
AGAINST CLINICALLY ISOLATED STAPHYLOCOCCUS AUREUS RESISTANT TO
FLUOROQUINOLONES TETREAU C, MOREAU N 208-209 J IN VITRO ACTIVITY OF
FLUOROQUINOLONES, FUSIDIC ACID AND RIFAMPICIN ; AGAINST NONGROWING
STAPHYLOCOCCI CARSENTI-ETESSE H, BERNARD E, PRADIER C, DURANT J,
BENSOUSSAN M, DELLAMONICA P CONTENTS 210 IN VITRO ANTIBACTERIAL ACTIVITY
OF LEVOFLOXACIN AGAINST MRSA YAMAJI E, AKIEDA Y, WATANABE T, SUZUKI T,
ITOKAWA K, TANAKA T, NAKAYAMA I 211-212 IN VITRO ANTIBACTERIAL ACTIVITY
OF AM-1155 AGAINST MRSA NAKAYAMA I, AKIEDA Y, WATANABE T, SUZUKI T,
ITOKAWA K, YAMAJI E 213-214 INFLUENCE OF EXOGENOUS FACTORS AND
ANTIBIOTICS ON THE CYTOPLASMIC MEMBRANE PROTEINS IN S. AUREUS CULLMANN
W, SCHLUNEGGER H QUINOLONE ACTIVITY AGAINST INTRACELLULAR PATHOGENS
INCLUDING MYCOBACTERIA 215-216 IN VITRO AND IN VIVO ACTIVITY OF AM-1155
AGAINST MYCOPLASMA PNEUMONIAE ISHIDA K, KAKU M, MATSUMOTO T, MIZUKANE R,
SUYAMA N, KOGA H, KOHNO S, HARA K 217-218 BACTERICIDAL ACTIVITY OF
OFLOXACIN, LEVOFLOXACIN AND OTHER FLUOROQUINOLONES COMPARED WITH AGENTS
PROVEN AGAINST LISTERIA MONOCYTOGENES CHERUBIN CE, STRATTON CW 219-220
ACTIVITY OF SPARFLOXACIN AND OTHER QUINOLONES AGAINST MYCOBACTERIA
MARTIN-LUENGO F, SEMPERE MA 221-222 ANTILEPROSY ACTION OF OFLOXACIN IN
COMBINATION WITH RIFAMPICIN OR DDS, AND BENZOXAZINORIFAMYCIN IN MICE,
AND THEIR IN VITRO ACTIVITIES AGAINST LEPROSY BACILLI TOMIOKA H, SAITO
H, SATO K, HIDAKA T 223-224 OFLOXACIN-BASED CHEMOTHERAPY IN MULTIPLY
DRUG-RESISTANT PULMONARY TUBERCULOSIS WILLCOX PA, GROENEWALD PJ,
MACKENZIE CR 225-226 CLINICAL TRIAL OF SPARFLOXACIN IN THE TREATMENT OF
LEPROSY FRANZBLAU SG, CHAN GP 227-228 FAILURE OF QUINOLONES ALONE AND IN
COMBINATION TO CURE EXPERIMENTAL MURINE BRUCELLOSIS : LANG R, SHASHA B,
KOLMAN S, RUBINSTEIN E IN VITRO LABORATORY STUDIES 229-231 ACTIVITY OF
CIPROFLOXACIN AGAINST RESPIRATORY PATHOGENS CAPABLE OF PRODUCING
/3-LACTAMASE SPECIALE A, CACCAMO F, DI MARCO R, BLANDINO G, NICOLETTI G
232-233 SENSITIVITY OF CIPROFLOXACIN-RESISTANT ISOLATES OF ACINETOBACTER
AND XANTHOMONAS TO 4 NEW QUINOLONES ROBERTS AP, TALBOYS CA, AZADIAN BS
234-235 IN VITRO EFFECT OF OFLOXACIN ALONE AND IN COMBINATION WITH
CEFTAZIDIME OR GENTAMICIN AGAINST P. AERUGINOSA SMITH KR, PATE MS, COBBS
CG, SAAG MS CONTENTS 236-237 BACTERICIDAL ACTIVITY OF FLUOROQUINOLONES
AGAINST ENTEROBACTERIA ISOLATED I FROM NOSOCOMIAL RESPIRATORY TRACT
INFECTIONS ALLOUCH PY, DECUYPER C, PANGON BH, BALLEREAU M, GHNASSIA JC
238-239 THE EFFECT OF OFLOXACIN ON PRODUCTION OF EXOENZYMES BY *
PSEUDOMONAS AERUGINOSA MIZUKANE R, KAKU M, ISHIDA K, KOGA H, KOHNO S,
HARA K 240-241 * RELEASE OF NEWER QUINOLONES FROM ACRYLIC BONE CEMENT
AND FIBRIN CLOTS IN VITRO KANELLAKOPOULOU K, TSOURVAKAS S,
HATZIGRIGORIS P, CHRYSSOULI Z, DOUNIS E, GIAMARELLOU H PHARMACODYNAMICS
242-243 PHARMACOKINETIC-BACTERICIDAL CORRELATIONS AFTER A SINGLE 200MG
IV DOSE OF CIPROFLOXACIN I DAN M, POCH F, QUASSEM C, KITZES R 472
COMPARATIVE PHARMACOKINETICS AND SERUM BACTERICIDAL ACTIVITIES (SBA) OF
CIPROFLOXACIN (C) AND OFLOXACIN (O) FOLLOWING SINGLE DOSE (ORAL [PO] AND
INTRAVENOUS [IV]) ADMINISTRATION WEINSTEIN MP, ECHOLS RM, KOWALSKY SF,
METIER AH 244 ! BACTERIAL KILLING AND REDUCTION IN BACTERIAL VIRULENCE
CONTRIBUTE TO THE ; EFFICACY OF QUINOLONES SONSTEIN SA, SWEENEY MT
245-246 A PHARMACOKINETIC METHOD OF ASSESSING ANTIBIOTICS EXHIBITING AN
; APPRECIABLE POSTANTIBIOTIC EFFECT LUBOWSKI TJ, NIGHTINGALE CH, SWEENEY
K, QUINTILIANI R 247 ; DOSAGE AND ADMINISTRATION OF OFLOXACIN IN
PATIENTS WITH CHRONIC RTI TSUBURA E, MASUNO T, FUJIMURA N
PHARMACOKINETICS: PENETRATION INTO BODY TISSUES AND FLUIDS 248-249 *
TISSUE DISTRIBUTION PHARMACOKINETICS OF CIPROFLOXACIN VS OFLOXACIN IN ;
RABBITS COLINO CI, SANCHEZ NAVARRO A, LANAO JM, DOMINGUEZ-GIL A 250
PROFILE OF CIPROFLOXACIN IN SERUM AND IN PLEURAL EXUDATE AFTER IV BOLUS
; INJECTION IN RATS ; MIGLIOLI PA, GHIOTTO E, GAION RM 251 J ABSORPTION
AND SECRETION OF SPARFLOXACIN IN THE ISOLATED RABBIT INTESTINAL TRACT
* HUNEAU J-F, TOME D, RAMON J, CARBON C, RUBINSTEIN E 252 ELIMINATION OF
LOMEFLOXACIN IN RAT INTESTINAL LOOP VERGIN H, METZ R, NAU R, KINZIG M,
SBRGEL F CONTENTS 253-254 SINGLE DOSE ORAL CIPROFLOXACIN FOR
PERIOPERATIVE ANTIBIOTIC PROPHYLAXIS IN LUNG SURGERY ROHWEDDER R, DELIA
TORRE H, SCHLECKER H 255-256 PERIOPERATIVE PROPHYLAXIS WITH OFLOXACIN IN
VASCULAR SURGERY: ANTIBIOTIC CONCENTRATIONS IN SERUM, LYMPH NODES AND
VESSEL WALL OLDORFP, WENDLING P 257-258 I PENETRATION OF OFLOXACIN INTO
HEART VALVES, MYOCARDIUM, MEDIASTINAL FAT AND STERNAL BONE MARROW IN MAN
MERTES PM, JEHL F, BURTIN P, DOPFF C, PINELLI G, VILLEMOT JP, MONTEIL M,
DUREUX JB 259 PENETRATION OF LEVOFLOXACIN INTO BRONCHOALVEOLAR LAVAGE
FLUID NAGAI H, YAMASAKI T, MASUDA M, GOTO Y, TASIRO T, NASU M 260-261
EXCRETION OF LEVOFLOXACIN INTO BILE AND GALLBLADDER TISSUE ; OHNISHI H,
TANIMURA H, ICHIMIYA G, AOKI Y, ISHIMOTO K, OKA S, KOBAYASHI Y, YAMAUE
H, , VCHIYAMA K, OCHIAI M, UENISHI M 262 ADMINISTRATION OF OFLOXACIN
BEFORE QUASI-ASEPTIC SURGERY * YAGYU T, KAWABATA A, KAWAKITA M, SHIMIZU
R, SUZUKI T 263-264 MONITORING BLOOD CONCENTRATIONS OF OFLOXACIN BY USE
OF SALIVA SHIBA K, YOSHIDA M, SAITO A, SAKAI O 470 COMPARISON OF BLISTER
FLUID PENETRATION OF FLEROXACIN AND ITS METABOLITES BETWEEN YOUNG AND
ELDERLY LEBEL M, KINZIG M, SBRGEL F : PHARMACOKINETICS IN DISEASE STATES
265 . CLINICAL EVALUATION OF OFLOXACIN AT A DAILY DOSAGE ADAPTED TO
CREATININE CLEARANCE IN ELDERLY SUBJECTS VEYSSIER P, MARTIN F, GALLINARI
C, MOULIAS R, CHAUVIN M, DELVAL C 266 J ACCUMULATION OF NEW QUINOLONES
IN THE BLOOD OF ELDERLY PATIENTS ; MORITA M, HASUDA A, NAKAGAWA H,
SUZUKI K 267-268 PHARMACOKINETICS OF OFLOXACIN IN PATIENTS WITH ACUTE
RENAL FAILURE UNDERGOING HAEMOFILTRATION SCHUSTER H, NEESER G,
HEHENBERGER H, LICHTWARCK M, ZICHNER M, ECKART J 269 LOMEFLOXACIN
PHARMACOKINETICS AFTER INTRAVENOUS AND ORAL ADMINISTRATION IN PATIENTS
WITH ACUTE PYELONEPHRITIS ! ROBSON RA, BAILEY RR, LYNN KL 270
EVALUATION OF CIPROFLOXACIN AND OFLOXACIN PHARMACOKINETICS IN ; LIVER
CIRRHOSIS MIGLIOLI PA, PALATINI P, ORLANDO R, SAWADOGO A 271-272
COMPARATIVE PHARMACOKINETICS OF ORAL AND INTRAVENOUS CIPROFLOXACIN
LETTIERI JT, KAISER L, KROL G, HELLER AH CONTENTS 273-274
PHARMACOKINETICS OF CIPROFLOXACIN AFTER SINGLE ORAL AND INTRAVENOUS
DOSES LETTIERI JT, ROGGE M, ECHOLS R, KAISER L, HELLER AH 275-276
CONCENTRATIONS OF OFLOXACIN IN BILE AND SERUM OF PATIENTS WITH BILIARY
TRACT DISEASES AND AN INDWELLING NASOBILIARY TUBE BUTTMANN A, KOHLER B,
SCHLAUCH D, RIEMANN JF, KINZIG M, SBRGEL F QUINOLONE TOXICITY AND
IMMUNOLOGICAL INTERACTIONS 277 IN VIVO EFFECT OF RUFLOXACIN AND
CIPROFLOXACIN ON T-CELL SUBSETS AND TUMOUR NECROSIS FACTOR PRODUCTION
GOLLAPUDI S, CHUAH S-K, THADEPALLI H, HARVEY T, THADEPALLI H 278-279
QUINOLONES AND INDUCTION OF UMUC AND MUTAGENICITY POWER EGM, PHILLIPS I
280-281 PRESERVATION OF CHEMILUMINESCENCE OF HUMAN LEUCOCYTES SUBJECTED
TO HYPEROSMOLALITY BY OFLOXACIN AND DR-3355 MATSUMOTO T, TAKAHASHI K,
KUBO S, HARAOKA M, TANAKA M, MIZUNOE Y, OGATA N, KUMAZAWA J 282
LOMEFLOXACIN-INDUCED PHOTOSENSITIVITY REACTION TOZAWA K, WASHIDA H
283-285 BINDING CAPACITY OF QUINOLONES TO CARTILAGE COMPONENTS FBRSTER
C, BAUMANN- WILSCHKE I, STAHLMANN R 286-287 LACK OF INFLUENCE OF
CIPROFLOXACIN ON THE EFFECTIVENESS OF ORAL CONTRACEPTIVES DROPPERT RM,
SCHOLIEN PC, ZWINKELS M, HOEPELMAN IM, TE VELDE ER 288 HEPATIC TOLERANCE
OF FLUOROQUINOLONE COMBINED WITH RIFAMPICIN IN OSTEOARTICULAR INFECTIONS
HALIMI R, CREMIEUX AC, A/NOT JY, CARBON C 289 * CLINICAL AND
HAEMATOLOGICAL SAFETY OF LONG TERM QUINOLONE TREATMENT LELEKIS M,
GARGALIANOS P, THANOS A, KOSMIDIS J 290-291 COMPARATIVE NEUROTOXICITY
STUDY OF CIPROFLOXACIN AND SPARFLOXACIN AFTER COADMINISTRATION WITH
FENBUFEN IN RATS IWAMOTO K, NAORA K, KATAGIRI Y, ICHIKAWA N, HAYASHIBARA
M, TANAKA K, YAMAGUCHI T, SEKINE Y 292 SYNAPTIC TRANSMISSION IN THE
HIPPOCAMPAL SLICE IN THE PRESENCE OF AMINOPHYLLINE ALONE AND IN
COMBINATION WITH QUINOLONES DIMPFEL W, DALHOFF A, HOFMANN W, SCHLUTER G
DRUG INTERACTIONS AND METABOLISM 293-294 INTERACTIONS OF DIFFERENT DRUGS
WITH THE N-DEMETHYLATION OF PEFLOXACIN IN THE RAT AS DETERMINED BY
ANALYSIS OF 14 CO2-EXHALATION CHRIST W, HECKER W, JACOBSEN M, KEMMLER H,
ESCH B CONTENTS 295-296 DOES A NONSTEROIDAL ANTI-INFLAMMATORY DRUG
MODIFY THE PHARMACOKINETICS OF PEFLOXACIN AND OFLOXACIN? ; FILLASTRE JP,
LEROY A, BORSA-LEBAS F, ETIENNE I, GY C, HUMBERT G 297-298 INFLUENCE
OF THE ZN-ANTIULCER AGENT ON CIPROFLOXACIN ABSORPTION IN : BEAGLE DOGS :
PALKA E, VODOPHEC P 471 INFLUENCE OF CIMETIDINE ON FLEROXACIN
PHARMACOKINETICS ; PORTMANN R 299-300 INFLUENCE OF ANTACIDS AND
RANITIDINE ON THE ABSORPTION OF * LEVOFLOXACIN IN MEN I SHIBA K, OKAZAKI
O, AOKI H, SHIMADA J, SAKAI O 301-302 PHARMACOKINETIC INTERACTION OF
TEMAFLOXACIN WITH CIMETIDINE IN HEALTHY VOLUNTEERS SAWAE Y 303-304 * A
METABOLITE OF SPARFLOXACIN IN URINE: PROPERTIES AND QUANTIFICATION ;
BORNER K, BORNER E, LODE H QUINOLONE USE IN IMMUNOCOMPROMISED PATIENTS
305-306 I COMPARISON OF EFFICACY AND SAFETY OF TREATMENT WITH OFLOXACIN-
I PIPERACILLIN AND AMIKACIN-PIPERACILLIN IN IMMUNODEPRESSED FEBRILE
NEUTROPENIC PATIENTS HAROUSSEAU JL, LAMAGNERE JP, BOASSON M, GUYOTAT D,
MOREAU P, LINASSIER C, LEVY S 307-308 EMPIRICAL TREATMENT OF PYREXIAL
NEUTROPENIC CANCER PATIENTS WITH ! PEFLOXACIN OR CEFTAZIDIME ;
PAPACHRISTODOULOU A, ALEXOPOULOS CG, VASLAMATZIS M 309-310 EFFECT OF
TOSUFLOXACIN TOSILATE IN THE PREVENTION OF SECONDARY INFECTIONS IN
PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES SAWADA H, TASHIMA M, YUMOTO Y,
OKUDA T, TOHI T, OKUMA M 311 | CIPROFLOXACIN PLUS VANCOMYCIN VS
CEFTAZIDIME PLUS GENTAMICIN IN THE ! TREATMENT OF PNEUMONIA IN
GRANULOCYTOPENIC PATIENTS KR CMERY JR V, FUCHSBERGER P, TRUPL J,
SUFLIARSKY J, SPANIK S, KOZA I, KUSENDA Z, KOREC S, SVEC J, BURKOVIC P,
LAKOTA J, HORNIKOVA M 312 QUINOLONES IN THE TREATMENT OF
COMMUNITY-ACQUIRED PNEUMONIA IN NEUTROPENIC PATIENTS KRCMERY JR V,
SPANIK S, MARDIAK J, FUCHSBERGER P, DANISOVICOVA A EYE AND ENT
INFECTIONS 313 INTRAOCULAR DIFFUSION OF IV OFLOXACIN IN PATIENTS AND
RABBITS MOUNIER M, CHAUVIN M, DENIS F, ADENIS JP, PLOY MC, MAES S
CONTENTS 314-315 THE INFLUENCE OF ACETAZOLAMIDE ON CIPROFLOXACIN AND
PEFLOXACIN PHARMACOKINETICS IN HUMAN AQUEOUS HUMOUR GIAMARELLOU H,
KANELLAS D, KAVOUKLIS E, DIMAKIS K, GABRIEL L 316-317 THERAPEUTIC
EFFICACY OF CIPROFLOXACIN IN PSEUDOMONAL OCULAR INFECTIONS IN A MURINE
MODEL ZEHAVI- WILLNER T, BARNEA A, LEVY Y 318-319 CLINICAL STUDY OF
SPARFLOXACIN IN OPHTHALMOLOGY OOISHI M AN D THE JAPANESE COLLABORATIVE
STUDY GROUP OF SPARFLOXACIN IN OPHTHALMOLOGY 320-321 ORAL PEFLOXACIN AND
OFLOXACIN IN THE TREATMENT OF MALIGNANT EXTERNAL OTITIS GALANAKIS N,
GIAMARELLOU H, CHRISTIDIS C, DOKIANAKIS G, SFIKAKIS P 322-323
PENETRATION AND CONCENTRATION OF OFLOXACIN IN NOSE AND EAR TISSUES
TOLSDORFFP 324 ORAL CIPROFLOXACIN VS CEFUROXIME AXETIL IN ACUTE
BACTERIAL SINUSITIS: A PILOT STUDY IN ADULTS KLEIN GL, HEYD A, ECHOLS R
325-326 CIPROFLOXACIN IN THE TREATMENT OF SUPPURATIVE OTITIS MEDIA AND
SINUSITIS MIYAMOTO N, KOBAYASHI T, BABA S 327-328 EFFICACY OF 2 REGIMENS
OF LOCAL CIPROFLOXACIN IN THE TREATMENT OF EAR INFECTIONS
GARCIA-RODRIGUEZ JA, DEL CAHIZO A, GARCIA SANCHEZ JE, GARCIA GARCIA MI,
DE MIGUEL MARTINEZ I, MUHOZ BELLIDO JL, GARCIA SANCHEZ E, RAMOS A
329-330 CLINICAL STUDIES OF SPARFLOXACIN IN THE FIELD OF
OTORHINOLARYNGOLOGY BABA S AND THE JAPANESE COLLABORATIVE STUDY GROUP OF
SPARFLOXACIN IN OTORHINOLARYNGOLOGY 331 CLINICAL STUDIES OF SPARFLOXACIN
IN ODONTOGENIC INFECTIONS SASAKI J AND THE JAPANESE COLLABORATIVE STUDY
GROUP OF SPARFLOXACIN IN ORAL SURGERY URINARY TRACT INFECTIONS 332
ACTIVITY OF PEFLOXACIN AFTER 2 YEARS SINGLE DOSE THERAPY FOR UTI
ALLOUCH PY, ALVAREZ JC, BARTHEL V, BENOIT M, BY L, COUDERC JP, DELAVAULT
P, DUBANCHET A, DORE A, * MATHONNET D, PANGON BH, ROUX JY, GHNASSIA JC
333-334 RANDOMISED COMPARISON OF ORAL CIPROFLOXACIN VS STANDARD
PARENTERAL . THERAPY IN THE TREATMENT OF COMPLICATED URINARY TRACT
INFECTIONS HARDING G, NICOLLE L, WENMAN W, RICHARDS G, LOUIE T, MARTEL
A, SIMOR A, SALIT I, GRIBBLE M 335-336 COMPARATIVE INVESTIGATION OF
OFLOXACIN 200MG ONCE DAILY AND LOOMG TWICE DAILY IN PATIENTS WITH
COMPLICATED URINARY TRACT INFECTIONS OSTRI P, HOLM-NIELSEN A, NERREGARD
P 337-338 EFFICACY AND SAFETY OF SINGLE DOSE ORAL PEFLOXACIN IN ACUTE
UNCOMPLICATED LOWER UTI SCHOLZ H-R, PRIEUR B-L AND THE PEFLOXACIN STUDY
GROUP * CONTENTS 339 SPARFLOXACIN IN THE TREATMENT OF GENITOURINARY
TRACT INFECTIONS KAWADA Y AND THE JAPANESE COLLABORATIVE STUDY GROUP OF
SPARFLOXACIN IN UROLOGY 340 SUPPRESSION OF RECURRENCE OF COMPLICATED UTI
BY LOW DOSE CIPROFLOXACIN KUMAZAWA J, MATSUMOTO T, TANAKA M, TAKAHASHI K
341-342 LOMEFLOXACIN VERSUS CIPROFLOXACIN IN THE TREATMENT OF
COMPLICATED OR RECURRENT UTI SAVITSKAYA KI, TRAPEZNIKOVA MF, NASONOV VN,
DUTOV VV, KALININ VN, NEHOROCHEVA AG, SOLODILOVA OE, SCHANIN AG,
RUSANOVA EV 343-344 LOMEFLOXACIN COMPARED WITH NORFLOXACIN FOR THE
TREATMENT OF URINARY TRACT INFECTIONS IN SPINAL INJURY PATIENTS TOSOLINI
FA, BROWN DJ 345-347 COMPARISON OF LOMEFLOXACIN AND COTRIMOXAZOLE IN THE
TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS LOUIE 77, NICOLLE L,
DUBOIS J, MARTEL A, SINAVE C, TOWNELL N, DELUNA M, SCOTT G, MICOUD M,
MOUTON Y, BADENOCK DF 348 COMBINED INTRAVENOUS AND ORAL TREATMENT IN
COMPLICATED UTI: LOMEFLOXACIN VS CIPROFLOXACIN MICHAELIS WE AND THE
LOMEFLOXACIN STUDY GROUP 349-350 PREVALENCE AND TREATMENT OF
ASYMPTOMATIC BACTERIURIA IN THE ELDERLY DEL RIO G, MESTRE J, DALET F 351
A COMPARATIVE STUDY WITH CIPROFLOXACIN IN PATIENTS WITH ACUTE
EPIDIDYMO-ORCHITIS REIFS, BORNMAN MS, MUTAMBIRWA S PROSTATITIS 352
SPARFLOXACIN, TEMAFLOXACIN, DIFLOXACIN, AND CIPROFLOXACIN IN THE
TREATMENT OF ACUTE PROSTATITIS : AN EXPERIMENTAL MODEL IN RATS GASSER
TC, DRESCHER P, MADSEN PO 353 OFLOXACIN IN PROSTATITIS AAGAARD J 354
PEFLOXACIN VS CEFTRIAXONE FOR ANTIMICROBIAL PROPHYLAXIS IN ENDOSCOPIC
UROLOGICAL SURGERY JIMENEZ-CRUZ JF, BROSETA E 355 OFLOXACIN PROPHYLAXIS
IN INFECTION AFTER TURP TOMA H, GOYA N, ITOH F, YANAGISAWA H, TOMOE H,
KIHARA T, OKUMURA T 356 CONCENTRATION OF OFLOXACIN IN PROSTATIC TISSUE
DURING TURP RIEDASCH G, MBHRING K, BRKOVIC D 357 SERUM AND PROSTATE
TISSUE CONCENTRATIONS OF OFLOXACIN FOLLOWING PROPHYLACTIC USE IN
TRANSURETHRAL RESECTION OF THE PROSTATE VAHLENSIECK JR W, KELLER HJ,
GROH R, DINKELDEIN V CONTENTS 358-359 ; ANALYSES OF PERIOPERATIVE
OFLOXACIN CONCENTRATIONS IN SERUM AND PROSTATE TISSUE HEINERT G, TAN TH,
THIELEN H, KRUGER J, WIIRTH G, ESSERS L 360-361 STUDY OF OFLOXACIN IN
COMPARISON WITH CEFTRIAXONE AS ANTIBIOTIC PROPHYLAXIS FOR STERILE URINE
TRANSURETHRAL RESECTION OF THE PROSTATE BUTREAU M, BOTTO H, DELVAL C,
LEVY S 362-363 TEMAFLOXACIN IN THE TREATMENT OF CHRONIC BACTERIAL
PROSTATITIS SUZUKI K, HORIBA M, TANAKA T, NAIDE Y, YONEZU M, YANAOKA M,
HIBI H 364-367 TREATMEN T OF CHRONIC BACTERIAL PROSTATITIS WITH
TOSUFLOXACIN * IKEUCHI T, KAWAMURA N, SUZUKI K, ONODERA S AND THE STUDY
GROUP ON CHRONIC BACTERIAL PROSTATITIS IN JAPAN 368-369 LEVOFLOXACIN
IN THE TREATMENT OF CHRONIC PROSTATITIS SUZUKI K, HORIBA M, TANAKA T,
NAIDE Y, YONETSU M STD - MALES 370 IN VITRO AND IN VIVO ACTIVITIES OF
SPARFLOXACIN AGAINST .. CHLAMYDIAL SPECIES KIMURA M, KISHIMOTO T,
HASHIGUCHI K, NIKI Y, SOEJIMA R 371 CLINICAL EXPERIENCE OF OFLOXACIN IN
THE TREATMENT OF NONGONOCOCCAL URETHRITIS CHEN M-T, CHANG C-P, LU C-C,
HUANG WJS, CHANG LS 372-373 CLINICAL EVALUATION OF OFLOXACIN IN MALE
URETHRITIS IN HONG KONG LO KK, LAI CF, TANG KC, NG PS, KAM KM 374
ANTIMICROBIAL ACTIVITY OF OFLOXACIN AGAINST NEISSERIA GONORRHOEAE AND
CHLAMYDIA TRACHOMATIS: CLINICAL EXPERIENCE IN JAPAN : SAITO I, SAIKO Y,
YOKOZAWA M, ONO K 375-376 MULTICENTRE STUDY OF OFLOXACIN IN MALE
URETHRITIS IN 7 ASIAN COUNTRIES KAWADA Y 377-378 QFLOXACIN IN THE
TREATMENT OF URETHRITIS IN MEN CHOI SK, LEE MS, HAN SW, HAN SS, LE HS
379 ACUTE NONGONOCOCCAL EPIDIDYMITIS: AETIOLOGY AND LEVOFLOXACIN THERAPY
SAITO I, SUZUKI A, SAIKO Y, YOKOZAWA M, ONO K 380-381 382-383 OBSTETRICS
AND GYNAECOLOGY RESPONSE OF VAGINAL FLORA TO TREATMENT OF CYSTITIS WITH
ENOXACIN OR AMOXICILLIN PETERSEN ME ANTIMICROBIAL ACTIVITY AND
PHARMACOKINETICS OF SPARFLOXACIN IN OBSTETRICS AND GYNAECOLOGY CHO N,
FUKUNAGA K, KUNII K CONTENTS 384 CLINICAL EXPERIENCE WITH SPARFLOXACIN
IN THE TREATMENT OF GYNAECOLOGICAL INFECTION MATSUDA S AND THE JAPANESE
COLLABORATIVE STUDY GROUP OF SPARFLOXACIN IN GYNECOLOGY 385 BASIC AND
CLINICAL STUDIES OF LEVOFLOXACIN IN OBSTETRICS AND GYNAECOLOGY YAMADA Y,
MIKAMO H, IZUMI K, ITO K, TAMAYA T SKIN AND SOFT TISSUE INFECTIONS 386
SPARFLOXACIN IN THE TREATMENT OF SKIN AND SOFT TISSUE INFECTIONS
TAKAHASHI H AND THE JAPANESE COLLABORATIVE STUDY GROUP OF SPARFLOXACIN
IN DERMATOLOGY 387 LOMEFLOXACIN VS CIPROFLOXACIN IN THE TREATMENT OF
NON-NECROTISING SKIN AND SKIN STRUCTURE INFECTIONS MCCARTY J 388-389 :
CLINICAL TRIALS OF A NEW QUINOLONE, SPARFLOXACIN, IN SKIN AND SKIN
STRUCTURE INFECTIONS WATANABE T, AKIEDA Y, SUZUKI T, ITOKAWA K, YAMAJI
E, NAKAYAMA I 390 LOMEFLOXACIN VS CIPROFLOXACIN IN THE TREATMENT OF
NON-NECROTISING SKIN AND SKIN STRUCTURE INFECTIONS MONROE A INTESTINAL
INFECTIONS 391-393 IN VITRO ACTIVITY OF QUINOLONES AGAINST CLINICAL
ISOLATES OF SALMONELLA TYPHI RESISTANT TO CHLORAMPHENICOL, AMPICILLIN
AND COTRIMOXAZOLE BARRIGA ANGULO G, ALARCBN OLIVARES N, CASTILLO TORRES
NP 394-395 MULTICENTRE CLINICAL STUDIES OF SPARFLOXACIN IN THE TREATMENT
OF INFECTIOUS ENTERITIS IMAGAWA Y AND THE JAPANESE COLLABORATIVE STUDY
GROUP OF SPARFLOXACIN ON INFECTIOUS ENTERITIS 396 EFFICACY AND SAFETY OF
PEFLOXACIN IN THE TREATMENT OF TYPHOID FEVER WAIZ A, SIDDIQUI M, HOSSAIN
M, CHAKRABORTY B 397 ] OFLOXACIN THERAPY OF SALMONELLA SPP. AND
PSEUDOMONAS PSEUDOMALLEI INFECTIONS (MELIOIDOSIS) IN PATIENTS WITH HIV
ANTIBODIES TANPHAICHITRA D, SRIMUANG S RESPIRATORY TRACT INFECTIONS -
BRONCHITIS 398 CLINICAL STUDY OF LONG TERM CIPROFLOXACIN THERAPY IN
DIFFUSE PANBRONCHIOLITIS TANIMOTO H, KOBAYASHI H, TAKIZAWA T, KABE J,
NAKATA K, KIRA S, SHISHIDO H, NAGANO H, KOBAYASHI S, HASEGAWA S, MAKINO
S, KURIYAMA T, MATSUI Y, OKANO H 399-400 OFLOXACIN AND ERYTHROMYCIN IN
THE MANAGEMENT OF DIFFUSE PANBRONCHIOLITIS SATO A, KAYAKAWA H, SUDA T
CONTENTS 413 418 OFLOXACIN AND MACROLIDES IN THE TREATMENT OF DIFFUSE
PANBRONCHIOLITIS TANABE O, KOMATUZAKI K, TADA H, SHIMIZU A, MOCHIZUKI T,
TANIMOTO H CIPROFLOXACIN IN THE TREATMENT OF EXACERBATIONS OF CHRONIC
RESPIRATORY TRACT INFECTIONS ODAGIRI S, TAKIGAMI T, FUKAYA K CLINICAL
RESPONSE TO SPARFLOXACIN IN RESPIRATORY TRACT INFECTIONS SOEJIMA R, HARA
K AND A JAPANESE COLLABORATIVE STUDY GROUP CIPROFLOXACIN IN THE
TREATMENT OF LOWER RESPIRATORY TRACT INFECTIONS MAZZEI JA, VUJACICH P,
FERNANDEZ A, TANCO J OFLOXACIN AND ERYTHROMYCIN IN ACUTE EXACERBATIONS
OF CHRONIC BRONCHITIS EGEDE F, NIELSEN PB, HUSFELDT P LOMEFLOXACIN VS
AMOXICILLIN IN PATIENTS WITH ACUTE EXACERBATIONS OF CHRONIC BRONCHITIS:
A UK MULTICENTRE STUDY HAMILTON BA, O BRYAN-TEAR CG, MARKANDAY S
LOMEFLOXACIN VS CIPROFLOXACIN IN LOWER RESPIRATORY INFECTION NONIKOV VE,
MAKAROVA OV, ZUBKOV MN, GUGUTZIDZE EN RUFLOXACIN VS AMOXICILLIN IN THE
TREATMENT OF ACUTE EXACERBATIONS OF CHRONIC BRONCHITIS KLIETMANN W,
FOCHT J, CESANA M OFLOXACIN VS CEFUROXIME IN THE TREATMENT OF LOWER
RESPIRATORY INFECTIONS IN MODERATELY IMMUNOCOMPROMISED PATIENTS LAM WK,
CHAU PY, CHAN JCK, IP MSM COMPARISON OF OFLOXACIN AND CEFACLOR IN THE
TREATMENT OF LOWER RESPIRATORY TRACT INFECTIONS IN ADULTS DARK DS,
FARBER M, RICE K RESPIRATORY TRACT INFECTIONS - PNEUMONIAS OFLOXACIN
COMBINED WITH AMOXICILLIN/CLAVULANIC ACID FOR EMPIRICAL TREATMENT OF
SEVERE COMMUNITY-ACQUIRED PNEUMONIA LE CHEVALIER B, GULLET E,
CHARBONNEAU P, BAZIN C, LEVY S, DELVAL C OFLOXACIN VS ERYTHROMYCIN IN
COMMUNITY-ACQUIRED PNEUMONIA IN GENERAL PRACTICE NIELSEN PB, HUSFELDT P,
EGEDE F EFFICACY AND SAFETY OF OFLOXACIN PLUS PIPERACILLIN IN THE
TREATMENT OF ASPIRATION PNEUMONIA NEVIERE R, HERENGT F, MATHIEU D,
WATTEL F ORAL CIPROFLOXACIN VS INTRAVENOUS CEFOTAXIME IN THE TREATMENT
OF PNEUMONIAS IN AIDS PATIENTS FRANZETTI F, CERNUSCHI M, RIDOLFO A,
ANTINORI S, COPPIN P, NEGRI C, MORONI M CONTENTS 427 ; EFFICACY AND
SAFETY OF OFLOXACIN IV IN VENTILATED PATIENTS WITH COPD AND EXACERBATION
OF PNEUMONIA ZIELMANN S, GROTE R, SYDOW M, SCHMIDT J, BURCHARDI H 473
CIPROFLOXACIN ERADICATES RESPIRATORY TRACT BACTERIA MORE RAPIDLY THAN
CEPHALOSPORINS IN PATIENTS WITH NOSOCOMIAL PNEUMONIA SCHENTAG JJ,
FORREST A, GOSS TF, LUZIER A, NIX DE, CUMBO TJ, FRACASSO JE, SANDS MF,
VANCE JW 28-429 CIPROFLOXACIN VS COMPARATIVE ANTIBIOTICS IN LRTI: A
META-ANALYSIS BYL B, KAUFMAN L, JACOBS F, DERDE MP, THYS JP DIVERSE
CLINICAL STUDIES 30-431 ORAL AND/OR INTRAVENOUS CIPROFLOXACIN FOR
TREATMENT OF MULTIPLY- RESISTANT FLAVOBACTERIUM MENINGOSEPTICUM
SEPTICAEMIA BOLASH NK, LIU HH *32-433 SAFETY AND EFFICACY OF PARENTERAL
FLEROXACIN VS CEFTAZIDIME IN MILD TO MODERATE LRTI AND SSTI AND
COMPLICATED UTI SHAHABUDDIN S, KARNIK A, KHAN FA 434 CLINICAL STUDIES OF
SPARFLOXACIN IN SURGICAL INFECTIONS YURA /AN D THE JAPANESE
COLLABORATIVE STUDY GROUP OF SPARFLOXACIN IN SURGERY 35-436 ONCE-DAILY
ADMINISTRATION OF LOMEFLOXACIN FOR INFECTIONS IN OLDER PATIENTS: A
SUMMARY OF WORLDWIDE CONTROLLED CLINICAL TRIALS MCCUE JD, RIZK E 37-438
INTRAVENOUS PEFLOXACIN VS CEFTRIAXONE IN THE TREATMENT OF NOSOCOMIAL
INFECTIONS PRESTERL E, GRANINGER W, FUEGGER R, BREYER S FLUOROQUINOLONES
IN THE TREATMENT OF NURSING HOME INFECTIONS MCCUE JD OVERVIEW OF
POSTMARKETING SURVEILLANCE OF OFLOXACIN IN JAPAN HANAFUSA T, SAWADA M,
SHIMIZU K, MAEDA Y, ARAUCHI T, KOBAYASHI T, OKADA S 43-444
AMOXICILLIN/CLAVULANIC ACID PLUS OFLOXACIN IN THE PREVENTION OF
INFECTION IN HEAD AND NECK SURGERY DE CHAMPS C, MIRAULT F, MANIPOUD P,
BARADUC R, RUSSIER M, COMMUN F, LAVERAN H 445 PREVENTION OF NOSOCOMIAL
INFECTIONS IN CIRRHOTIC PATIENTS WITH GASTROINTESTINAL HAEMORRHAGE
BLAISE M, LEVACHER S, PATERON D, COLLIGNON A, POURRIAT JL 46-447
ONCE-DAILY OFLOXACIN VS TWICE-DAILY CIPROFLOXACIN IN THE TREATMENT OF ,;
HOSPITAL INFECTIONS I KITZES-COHEN R, LAOR A, RAZ R BONE AND JOINT
INFECTIONS 48-449 COMPARATIVE PENETRATION OF 3 FLUOROQUINOLONES INTO
HUMAN CRANIAL BONE TISSUE AFTER ADMINISTRATION OF A SINGLE INTRAVENOUS
DOSE DESBORDES JM, BOUQUET S, BREUX JP, CHAPELLE G, BATAILLE B, BECQ
GIRAUDON B, FUSCIARDI J CONTENTS 450-451 PHARMACOKINETICS OF INTRAVENOUS
OFLOXACIN IN PATIENTS UNDERGOING TOTAL HIP ENDOPROSTHESIS KAPFER X, HAHN
F, DINKELDEIN U, LUCKE C 452-453 TREATMENT OF CHRONIC REACTIVE ARTHRITIS
WITH A 3-MONTH COURSE OF CIPROFLOXACIN YLI-KERTTULA T, LUUKKAINEN R,
MERILAHTI-PALO R, GRANFORS K, SEPPALA J, TOIVANEN A 454-455
CIPROFLOXACIN IN THE TREATMENT OF CHRONIC OSTEOMYELITIS IN ADULTS
/.MALA TRUJILLO I, VALLADARES G, NAVA A 456-457 PEFLOXACIN IN THE
TREATMENT OF OSTEOMYELITIS GOMIS M, BARBERAN J, LBPEZ-ARCEO J, PASTOR JM
458 FLUOROQUINOLONES IN THE MANAGEMENT OF JOINT-PROSTHESIS INFECTION
CREMIEUX AC, DELAGE A, OBERLIN C, ALNOT JY, CARBON C PAEDIATRICS 459-460
PEFLOXACIN AFTER FAILURE OF INITIAL ANTIBIOTIC THERAPY IN CHILDREN WITH
SEVERE INVASIVE SALMONELLOSIS GENDREL D, RAYMOND J, LEGAL! M-A, BERGERET
M, BADOUAL J 461-462 CIPROFLOXACIN USE DURING PREGNANCY BOMFORD JAL,
LEDGER JC, O KEEFFE BJ, REITER CH COST/BENEFIT EFFECT 463 COMPARISON OF
CIPROFLOXACIN WITH NETILMICIN IN THE TREATMENT OF ACUTE PYELONEPHRITIS:
REDUCING HOSPITAL STAY BAILEY RR, LYNN KL, ROBSON RA, PEDDLE BA, SMITH A
; 464 SHORTENED HOSPITAL STAY WITH SEQUENTIAL INTRAVENOUS/ORAL
CIPROFLOXACIN CHRYSANTHOPOULOS CJ, SKOUTELIS A T, BASSARIS HP 474
ECONOMIC IMPACT OF IV AND IV-TO-PO SEQUENTIAL CIPROFLOXACIN VS STANDARD
IV ANTIBIOTICS PALADINO JA, VAN SLOOTEN A 475 ABBREVIATING THE DURATION
OF INTRAVENOUS ANTIBIOTICS WITH ORAL FLUOROQUINOLONES PALADINO JA, CUMBO
77, SCHENTAG JJ, BLOOM MJ, SERRIANNE DJ, BURNETT GJ 465-466 AN ECONOMIC
ASSESSMENT OF OFLOXACIN REINHART SP, TROTTER JP 467 I SEQUENTIAL THERAPY
.WITH INTRAVENOUS AND ORAL OFLOXACIN IN SEVERE ENT INFECTIONS KMENT G,
KORNFEHL J, GLATZ H 468-469 SURGICAL INFECTIONS TREATED PARENTERALLY
WITH OFLOXACIN PRESTERL E, TELEKY B, WINKLER S, BREYER S, GRANINGER W
|
| any_adam_object | 1 |
| author_corporate | International Symposium on New Quinolones München |
| author_corporate_role | aut |
| author_facet | International Symposium on New Quinolones München |
| author_sort | International Symposium on New Quinolones München |
| building | Verbundindex |
| bvnumber | BV008163353 |
| ctrlnum | (OCoLC)231552544 (DE-599)BVBBV008163353 |
| format | Conference Proceeding Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01634nam a2200361 cb4500</leader><controlfield tag="001">BV008163353</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20040227 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">930809s1993 ad|| |||| 10||| eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)231552544</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV008163353</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-19</subfield><subfield code="a">DE-12</subfield><subfield code="a">DE-355</subfield></datafield><datafield tag="111" ind1="2" ind2=" "><subfield code="a">International Symposium on New Quinolones</subfield><subfield code="n">4</subfield><subfield code="d">1992</subfield><subfield code="c">München</subfield><subfield code="j">Verfasser</subfield><subfield code="0">(DE-588)1300985-0</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">4th International Symposium on New Quinolones</subfield><subfield code="b">proceedings of a the 4th International Symposium on New Quinolones held at Munich, Germany, August 27 - 29, 1992</subfield><subfield code="c">organising committee E. Rubinstein (chairman) ...</subfield></datafield><datafield tag="246" ind1="1" ind2="3"><subfield code="a">Fourth International Symposium on New Quinolones</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Auckland [u.a.]</subfield><subfield code="b">Adis Internat.</subfield><subfield code="c">1993</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XX, 475 S.</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Drugs : Supplement</subfield><subfield code="v">45,3</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Literaturangaben</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Gyrasehemmer</subfield><subfield code="0">(DE-588)4217839-3</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)1071861417</subfield><subfield code="a">Konferenzschrift</subfield><subfield code="y">1992</subfield><subfield code="z">München</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Gyrasehemmer</subfield><subfield code="0">(DE-588)4217839-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rubinstein, Ethan</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Drugs</subfield><subfield code="v">Supplement ; 45,3</subfield><subfield code="w">(DE-604)BV000904909</subfield><subfield code="9">45,3</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">GBV Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=005385939&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-005385939</subfield></datafield></record></collection> |
| genre | (DE-588)1071861417 Konferenzschrift 1992 München gnd-content |
| genre_facet | Konferenzschrift 1992 München |
| id | DE-604.BV008163353 |
| illustrated | Illustrated |
| indexdate | 2024-07-09T17:15:35Z |
| institution | BVB |
| institution_GND | (DE-588)1300985-0 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-005385939 |
| oclc_num | 231552544 |
| open_access_boolean | |
| owner | DE-19 DE-BY-UBM DE-12 DE-355 DE-BY-UBR |
| owner_facet | DE-19 DE-BY-UBM DE-12 DE-355 DE-BY-UBR |
| physical | XX, 475 S. Ill., graph. Darst. |
| publishDate | 1993 |
| publishDateSearch | 1993 |
| publishDateSort | 1993 |
| publisher | Adis Internat. |
| record_format | marc |
| series | Drugs |
| series2 | Drugs : Supplement |
| spelling | International Symposium on New Quinolones 4 1992 München Verfasser (DE-588)1300985-0 aut 4th International Symposium on New Quinolones proceedings of a the 4th International Symposium on New Quinolones held at Munich, Germany, August 27 - 29, 1992 organising committee E. Rubinstein (chairman) ... Fourth International Symposium on New Quinolones Auckland [u.a.] Adis Internat. 1993 XX, 475 S. Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Drugs : Supplement 45,3 Literaturangaben Gyrasehemmer (DE-588)4217839-3 gnd rswk-swf (DE-588)1071861417 Konferenzschrift 1992 München gnd-content Gyrasehemmer (DE-588)4217839-3 s DE-604 Rubinstein, Ethan Sonstige oth Drugs Supplement ; 45,3 (DE-604)BV000904909 45,3 GBV Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=005385939&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | 4th International Symposium on New Quinolones proceedings of a the 4th International Symposium on New Quinolones held at Munich, Germany, August 27 - 29, 1992 Drugs Gyrasehemmer (DE-588)4217839-3 gnd |
| subject_GND | (DE-588)4217839-3 (DE-588)1071861417 |
| title | 4th International Symposium on New Quinolones proceedings of a the 4th International Symposium on New Quinolones held at Munich, Germany, August 27 - 29, 1992 |
| title_alt | Fourth International Symposium on New Quinolones |
| title_auth | 4th International Symposium on New Quinolones proceedings of a the 4th International Symposium on New Quinolones held at Munich, Germany, August 27 - 29, 1992 |
| title_exact_search | 4th International Symposium on New Quinolones proceedings of a the 4th International Symposium on New Quinolones held at Munich, Germany, August 27 - 29, 1992 |
| title_full | 4th International Symposium on New Quinolones proceedings of a the 4th International Symposium on New Quinolones held at Munich, Germany, August 27 - 29, 1992 organising committee E. Rubinstein (chairman) ... |
| title_fullStr | 4th International Symposium on New Quinolones proceedings of a the 4th International Symposium on New Quinolones held at Munich, Germany, August 27 - 29, 1992 organising committee E. Rubinstein (chairman) ... |
| title_full_unstemmed | 4th International Symposium on New Quinolones proceedings of a the 4th International Symposium on New Quinolones held at Munich, Germany, August 27 - 29, 1992 organising committee E. Rubinstein (chairman) ... |
| title_short | 4th International Symposium on New Quinolones |
| title_sort | 4th international symposium on new quinolones proceedings of a the 4th international symposium on new quinolones held at munich germany august 27 29 1992 |
| title_sub | proceedings of a the 4th International Symposium on New Quinolones held at Munich, Germany, August 27 - 29, 1992 |
| topic | Gyrasehemmer (DE-588)4217839-3 gnd |
| topic_facet | Gyrasehemmer Konferenzschrift 1992 München |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=005385939&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV000904909 |
| work_keys_str_mv | AT internationalsymposiumonnewquinolonesmunchen 4thinternationalsymposiumonnewquinolonesproceedingsofathe4thinternationalsymposiumonnewquinolonesheldatmunichgermanyaugust27291992 AT rubinsteinethan 4thinternationalsymposiumonnewquinolonesproceedingsofathe4thinternationalsymposiumonnewquinolonesheldatmunichgermanyaugust27291992 AT internationalsymposiumonnewquinolonesmunchen fourthinternationalsymposiumonnewquinolones AT rubinsteinethan fourthinternationalsymposiumonnewquinolones |